Overview

Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate Arimidex 6 month therapy as an adjuvant treatment in postmenopausal patients with advanced breast cancer in whom a partial or complete response or stabilized disease were obtained with first line chemotherapy, by tumoral response assessment.
Details
Lead Sponsor:
AstraZeneca
Treatments:
Anastrozole